Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples

Invasive infections caused by carbapenemase-producing bacteria are associated with excess mortality. We applied a rapid diagnostic test (RDT) on clinical samples with an elevated likelihood of carbapenemase-producing bacteria and documented its impact on antibiotic treatment decisions. Among 38 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Sophie, Berger, Fabian K., Link, Andreas, Nimmesgern, Anna, Lepper, Philipp M., Murawski, Niels, Bittenbring, Jörg T., Becker, Sören L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817559/
https://www.ncbi.nlm.nih.gov/pubmed/32895756
http://dx.doi.org/10.1007/s10096-020-04021-4
_version_ 1783638665395699712
author Roth, Sophie
Berger, Fabian K.
Link, Andreas
Nimmesgern, Anna
Lepper, Philipp M.
Murawski, Niels
Bittenbring, Jörg T.
Becker, Sören L.
author_facet Roth, Sophie
Berger, Fabian K.
Link, Andreas
Nimmesgern, Anna
Lepper, Philipp M.
Murawski, Niels
Bittenbring, Jörg T.
Becker, Sören L.
author_sort Roth, Sophie
collection PubMed
description Invasive infections caused by carbapenemase-producing bacteria are associated with excess mortality. We applied a rapid diagnostic test (RDT) on clinical samples with an elevated likelihood of carbapenemase-producing bacteria and documented its impact on antibiotic treatment decisions. Among 38 patients, twelve tested positive for infections caused by carbapenemase-producing bacteria (31.6%), mainly in blood cultures. KPC (n = 10) was more frequent than OXA-48 (n = 2). RDT-based carbapenemase detection led to a treatment modification to ceftazidime/avibactam-containing regimens in all patients before detailed antibiotic testing results became available. Eleven patients (92%) survived the acute infection, whereas one patient with a ceftazidime/avibactam- and colistin-resistant OXA-48-positive isolate died.
format Online
Article
Text
id pubmed-7817559
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78175592021-01-25 Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples Roth, Sophie Berger, Fabian K. Link, Andreas Nimmesgern, Anna Lepper, Philipp M. Murawski, Niels Bittenbring, Jörg T. Becker, Sören L. Eur J Clin Microbiol Infect Dis Brief Report Invasive infections caused by carbapenemase-producing bacteria are associated with excess mortality. We applied a rapid diagnostic test (RDT) on clinical samples with an elevated likelihood of carbapenemase-producing bacteria and documented its impact on antibiotic treatment decisions. Among 38 patients, twelve tested positive for infections caused by carbapenemase-producing bacteria (31.6%), mainly in blood cultures. KPC (n = 10) was more frequent than OXA-48 (n = 2). RDT-based carbapenemase detection led to a treatment modification to ceftazidime/avibactam-containing regimens in all patients before detailed antibiotic testing results became available. Eleven patients (92%) survived the acute infection, whereas one patient with a ceftazidime/avibactam- and colistin-resistant OXA-48-positive isolate died. Springer Berlin Heidelberg 2020-09-07 2021 /pmc/articles/PMC7817559/ /pubmed/32895756 http://dx.doi.org/10.1007/s10096-020-04021-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Report
Roth, Sophie
Berger, Fabian K.
Link, Andreas
Nimmesgern, Anna
Lepper, Philipp M.
Murawski, Niels
Bittenbring, Jörg T.
Becker, Sören L.
Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title_full Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title_fullStr Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title_full_unstemmed Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title_short Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
title_sort application and clinical impact of the resist-4 o.k.n.v. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817559/
https://www.ncbi.nlm.nih.gov/pubmed/32895756
http://dx.doi.org/10.1007/s10096-020-04021-4
work_keys_str_mv AT rothsophie applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT bergerfabiank applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT linkandreas applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT nimmesgernanna applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT lepperphilippm applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT murawskiniels applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT bittenbringjorgt applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples
AT beckersorenl applicationandclinicalimpactoftheresist4oknvrapiddiagnostictestforcarbapenemasedetectioninbloodculturesandclinicalsamples

Ejemplares similares